Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program
Sign Up to like & getrecommendations! Published in 2021 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13236
Abstract: The CANVAS Program identified the effect of canagliflozin on major adverse cardiovascular events (MACE) differed according to whether participants were using diuretics at study commencement. We sought to further evaluate this finding related to baseline… read more here.
Keywords: canvas program; renal outcomes; canvas; cardiovascular renal ... See more keywords
Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2707
Abstract: Empagliflozin improves cardiovascular and renal outcomes in patients with heart failure (HF) and reduced ejection fraction (HFrEF), but its efficacy and safety across patient's age is not well established. read more here.
Keywords: heart failure; failure reduced; renal outcomes; heart ... See more keywords
Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain.
Sign Up to like & getrecommendations! Published in 2019 at "Enfermedades infecciosas y microbiologia clinica"
DOI: 10.1016/j.eimc.2018.09.015
Abstract: BACKGROUND The life expectancy of HIV-infected individuals has dramatically improved with potent antiretroviral therapies. However, organ-specific toxicities of some antiretrovirals and persistent inflammation and immune activation due to residual virus replication account for a high… read more here.
Keywords: antiretroviral therapy; infected individuals; renal bone; cardiovascular renal ... See more keywords
EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)32479-7
Abstract: Canagliflozin (CANA) reduces the risk of cardiovascular (CV) events and kidney failure in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Inherent in its mechanism of action is enhanced natriuresis and… read more here.
Keywords: canagliflozin cardiovascular; safety outcomes; renal safety; safety ... See more keywords
Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection
Sign Up to like & getrecommendations! Published in 2021 at "Blood Pressure"
DOI: 10.1080/08037051.2021.1975878
Abstract: There is a clear-cut need to improve prevention of cardiovascular and renal diseases. Several interventions focused on hypertension-mediated risk reduction have been advocated including multi-omics approach, home blood pressure telemonitoring and patient empowerment. Genetics, metabolomics… read more here.
Keywords: home blood; cardiovascular renal; trial; blood pressure ... See more keywords
CENTRAL AND BRACHIAL PULSE PRESSURE PREDICTS CARDIOVASCULAR AND RENAL EVENTS IN TREATED HYPERTENSIVE PATIENTS
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Hypertension"
DOI: 10.1080/08037051.2022.2062295
Abstract: Objective: Central blood pressure is a stronger predictor of cardiovascular prognosis rather than brachial blood pressure. Reflection wave reaches abdominal aorta sooner than ascending aorta. Thus, the contribution of central pulse pressure (cPP) to renal… read more here.
Keywords: central brachial; pressure; renal events; brachial pulse ... See more keywords
Early Age-related Macular Degeneration with Cardiovascular and Renal Comorbidities: An Analysis of the National Health and Nutrition Examination Survey, 2005–2008
Sign Up to like & getrecommendations! Published in 2017 at "Ophthalmic Epidemiology"
DOI: 10.1080/09286586.2017.1337911
Abstract: ABSTRACT Purpose: A cross sectional study was designed to examine the relationship of early age-related macular degeneration (AMD) with comorbidities of cardiovascular and renal conditions in the representative population using National Health and Nutrition Examination… read more here.
Keywords: age related; early age; cardiovascular renal; early amd ... See more keywords
Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2020.1822327
Abstract: ABSTRACT Introduction A growing number of antidiabetic agents have demonstrated cardiovascular and renal benefits in cardiovascular outcome trials (CVOTs), despite such trials being principally required to rule out excess cardiovascular risk. Areas covered This article… read more here.
Keywords: trial; vertis trial; renal outcomes; cardiovascular renal ... See more keywords
MO129COMPARATIVE EFFECTIVENESS OF SGLT2I VERSUS DPP4I ON CARDIOVASCULAR AND RENAL OUTCOMES IN ROUTINE-CARE SETTINGS
Sign Up to like & getrecommendations! Published in 2021 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfab092.007
Abstract: While clinical trials have demonstrated the efficacy of SGLT2 inhibitors on preventing cardiovascular and renal damage, few studies have expanded this evidence to routine-care settings. We compared clinical outcomes of adults who started SGLT2i or… read more here.
Keywords: sglt2i; routine care; dpp4i; cardiovascular renal ... See more keywords
Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care.
Sign Up to like & getrecommendations! Published in 2020 at "Current Opinion in Cardiology"
DOI: 10.1097/hco.0000000000000774
Abstract: PURPOSE OF REVIEW The management of individuals who live with type 2 diabetes requires an integrated and multifaceted approach. RECENT FINDINGS Sodium-glucose cotransporter 2 inhibitors effectively prevent and treat cardiorenal complications in the presence of… read more here.
Keywords: care; cotransporter inhibitors; renal metabolic; sodium glucose ... See more keywords
Effects of sodium‐glucose cotransporter‐2 inhibitors on the cardiovascular and renal complications of type 2 diabetes
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.1111/dom.13854
Abstract: Sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) have been shown to mitigate the risks of cardiovascular (CV) and renal complications in patients with type 2 diabetes (T2D) and CV risk factors or CV disease (CVD). In CV outcomes… read more here.
Keywords: risk; sodium glucose; cotransporter inhibitors; renal complications ... See more keywords